Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
PRVB Provention Bio, Inc. daily Stock Chart
PRVB [NASD]
Provention Bio, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-1.02 Insider Own11.10% Shs Outstand44.28M Perf Week-3.12%
Market Cap357.34M Forward P/E- EPS next Y-1.12 Insider Trans0.00% Shs Float32.29M Perf Month34.05%
Income-38.40M PEG- EPS next Q-0.24 Inst Own10.60% Short Float5.40% Perf Quarter-16.80%
Sales- P/S- EPS this Y-182.30% Inst Trans33.55% Short Ratio3.92 Perf Half Y112.37%
Book/sh2.26 P/B3.57 EPS next Y-0.90% ROA-60.90% Target Price21.83 Perf Year178.28%
Cash/sh2.15 P/C3.76 EPS next 5Y- ROE-64.70% 52W Range1.52 - 22.82 Perf YTD355.93%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-64.64% Beta-
Dividend %- Quick Ratio19.40 Sales past 5Y- Gross Margin- 52W Low430.92% ATR0.63
Employees13 Current Ratio19.40 Sales Q/Q- Oper. Margin- RSI (14)57.10 Volatility7.72% 9.12%
OptionableYes Debt/Eq0.00 EPS Q/Q-50.80% Profit Margin- Rel Volume0.54 Prev Close7.50
ShortableYes LT Debt/Eq0.00 EarningsNov 05 AMC Payout- Avg Volume444.25K Price8.07
Recom1.70 SMA2013.14% SMA506.25% SMA20023.07% Volume241,395 Change7.60%
Jun-26-19Reiterated H.C. Wainwright Buy $8 → $20
Jun-10-19Initiated Chardan Capital Markets Buy $20
Feb-22-19Initiated SVB Leerink Outperform $6
Nov-05-19 04:05PM  Provention Bio Reports Third Quarter 2019 Financial Results PR Newswire
Oct-29-19 12:52PM  Will Provention Bio (NASDAQ:PRVB) Spend Its Cash Wisely? Simply Wall St.
07:00AM  Provention Bio to Report Third Quarter 2019 Financial Results and Host Conference Call on Tuesday, November 5, 2019 PR Newswire
Oct-24-19 07:00AM  Provention Bio Announces PRV-031 (Teplizumab) Granted PRIME Designation by the European Medicines Agency PR Newswire
Oct-22-19 07:00AM  Provention Bio Reports Top Line Results from Phase 2a PRINCE Clinical Trial with PRV-6527, an Oral CSF-1R Inhibitor, in Patients with Moderate to Severe Crohn's Disease PR Newswire
Sep-26-19 07:00AM  Sean Doherty Joins Provention Bio Board of Directors PR Newswire
Sep-25-19 07:00AM  Provention Bio to Present at the 2019 Cantor Global Healthcare Conference PR Newswire
Sep-24-19 07:00AM  Provention Bio Reiterates Regulatory Strategy for PRV-031 and Announces Completion of Follow-on Financing PR Newswire
Sep-19-19 07:39AM  The Daily Biotech Pulse: China Biologics Receives Buyout Offer, Provention Bio Offering, Exagen IPO Benzinga -14.18%
Sep-18-19 08:26PM  Provention Bio Announces Pricing of $40 Million Public Offering of Common Stock PR Newswire
04:14PM  Provention Bio Announces Proposed Public Offering of Common Stock PR Newswire
Aug-27-19 03:30PM  Need To Know: Provention Bio, Inc. (NASDAQ:PRVB) Insiders Have Been Buying Shares Simply Wall St.
Aug-20-19 07:00AM  Provention Bio Announces Key Addition to its Leadership Team PR Newswire
Aug-09-19 08:15AM  Provention Bio Inc (PRVB) President and CEO Ashleigh Palmer Bought $96,990 of Shares GuruFocus.com +7.61%
Aug-08-19 07:00AM  Provention Bio Initiates Phase 1b/2a PREVAIL Clinical Trial Evaluating PRV-3279 in Lupus PR Newswire
Aug-06-19 07:00AM  Provention Bio Reports Second Quarter 2019 Financial Results PR Newswire -10.27%
Aug-05-19 12:21PM  A Look At Benzinga Pro's Most-Searched Tickers For August 5, 2019 Benzinga -6.76%
07:00AM  Provention Bio Announces Breakthrough Therapy Designation for Teplizumab (PRV-031) for the Prevention or Delay of Clinical Type 1 Diabetes in At-Risk Individuals PR Newswire
Jul-12-19 07:15AM  5 Best Biotech Stocks of 2019 So Far Motley Fool +6.48%
Jul-01-19 07:30AM  ActoBio Therapeutics Progresses AG019 to Next Stage of a Phase Ib/IIa Clinical Study for the Treatment of Type 1 Diabetes PR Newswire
Jun-14-19 12:31PM  Why Consistent Trading Doesn't Always Lead To Consistent Results Benzinga
Jun-13-19 07:49AM  Provention Bio Cancels Secondary Offering, Shares Rally Benzinga -5.40%
07:27AM  Provention Bio's stock surges after calling off public stock offering MarketWatch
07:00AM  Provention Bio Announces Termination of Public Offering of Common Stock PR Newswire
Jun-12-19 08:44AM  2 Small Biotechs With Sagging Shares but Promising Prospects TheStreet.com
Jun-11-19 09:43AM  Company News For Jun 11, 2019 Zacks -12.62%
07:34AM  The Daily Biotech Pulse: Lilly Reports Positive Long-Term Efficacy Data For Psoriasis Drug, Provention Bio Offering Benzinga
Jun-10-19 05:32PM  Provention Bio Announces Proposed Public Offering of Common Stock PR Newswire +217.01%
01:04PM  Provention Bio News: Why PRVB Stock Is Skyrocketing Today InvestorPlace
Jun-09-19 01:05PM  A Single Course of Provention's PRV-031 (Teplizumab) Delays Type 1 Diabetes Onset in High-Risk Individuals by at Least Two Years PR Newswire
May-27-19 11:02AM  Could The Provention Bio, Inc. (NASDAQ:PRVB) Ownership Structure Tell Us Something Useful? Simply Wall St.
May-09-19 07:56AM  The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut Benzinga -27.45%
May-08-19 04:30PM  Provention Bio Reports First Quarter 2019 Financial Results PR Newswire
04:25PM  Provention Bio Announces Top-Line Results from its Phase 1b PULSE Clinical Trial of PRV-300 in Patients with Moderate-to-Severe Ulcerative Colitis PR Newswire
Apr-24-19 07:00AM  Provention Bio Completes Enrollment of Phase 2a PRINCE Clinical Trial with PRV-6527 in Patients with Moderate to Severe Crohn's Disease PR Newswire
Apr-12-19 09:49AM  Provention Bio, Inc. (PRVB) Shares March Higher, Can It Continue? Zacks
Apr-09-19 07:00AM  Provention Bio Initiates Phase 3 PROTECT Clinical Trial with PRV-031 (Teplizumab) in Patients with Recent Onset Type 1 Diabetes PR Newswire +15.95%
Apr-02-19 07:00AM  Provention Bio Announces Key Additions to its Senior Management Team PR Newswire
Mar-28-19 07:00AM  Provention Bio Appoints Jeffrey Bluestone, PhD, to Board of Directors PR Newswire
Mar-19-19 04:05PM  Provention Bio Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update PR Newswire
Mar-12-19 04:05PM  Provention Bio to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Tuesday, March 19, 2019 PR Newswire
Feb-13-19 07:33AM  Provention Bio To Present at 8th Annual Leerink Partners Global Healthcare Conference PR Newswire +5.33%
Jan-28-19 07:33AM  Provention Bio Receives Notice of Allowance from United States Patent and Trademark Office for Patent on Multi-Strain Coxsackievirus B Vaccine for Preventing or Treating Type 1 Diabetes (T1D) PR Newswire
Jan-03-19 07:33AM  Provention Bio Announces Publication in "Expert Review of Vaccines" Describing the Scientific Rationale for Developing a Vaccine for Type 1 Diabetes by Targeting Coxsackievirus B PR Newswire
Dec-25-18 10:46AM  Are Insiders Buying Provention Bio, Inc. (NASDAQ:PRVB) Stock? Simply Wall St.
Nov-28-18 07:33AM  Provention Bio Joins the C-Path Type 1 Diabetes (T1D) Consortium PR Newswire
Nov-08-18 07:33AM  Provention Bio Reports Third Quarter 2018 Financial Results and Provides Business Update PR Newswire -6.47%
Nov-05-18 09:00AM  Amgen And Provention Bio Announce Co-Development Collaboration In Celiac Disease PR Newswire +13.00%
Oct-23-18 07:33AM  Provention Bio Announces Completion of Enrollment of Phase 1b Clinical Trial of PRV-300 in Moderate-to-Severe Ulcerative Colitis PR Newswire -5.19%
Sep-11-18 07:33AM  Provention Bio To Present at 2018 Janney Healthcare Conference PR Newswire
Sep-05-18 07:33AM  Provention Bio Appoints Accomplished Biotech Executive, Chip Catlin, to its Board of Directors PR Newswire
Aug-13-18 08:00AM  Provention Bio Reports Second Quarter 2018 Financial Results and Provides Business Update PR Newswire +5.71%
Jul-31-18 07:33AM  Provention Bio Appoints Leading T1D Expert, Dr. Mark Rigby, as Vice President, Clinical Development PR Newswire
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, an oral CSF-1R inhibitor, which is in Phase IIa clinical trial for the treatment of Crohn's disease; PRV-300, an anti-TLR3 mAb, which is in Phase Ib clinical trial for the treatment of ulcerative colitis; PRV-3279, which is in phase Ib/IIa for the treatment of lupus; PRV-101, a multivalent coxsackie virus vaccine for the prevention of acute Coxsackie Virus B Vaccine and the prevention of the onset of T1D; and PRV-015, which is in phase IIb for the treatment of gluten-free diet non-responding celiac disease. The company has a licensing and co-development agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease. Provention Bio, Inc. was incorporated in 2016 and is based in Oldwick, New Jersey.
open in yahoo | open in reuters | open in google